| Catalog No. | HF004046 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Chimeric |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | HER1, Receptor tyrosine-protein kinase erbB-1, Proto-oncogene c-ErbB-1, Epidermal growth factor receptor, EGFR, ERBB1, ERBB |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P00533 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -282°C. |
|---|
| Alternate Names | DS1024,Sym004(combinationofmodotuximabandfutuximab),CAS:1310460-86-6 |
|---|
| Background | Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
